IQHQ adds Janice Sears and Anshul Mangal to its Board as Independent Directors

– USA, CA –  IQHQ, Inc., a premier life sciences real estate development company, today announced the appointments of Janice Sears and Anshul Mangal to its Board as independent directors, bringing decades of relevant life science and commercial real estate experience.

“We are pleased to add Janice and Anshul to our esteemed Board of Directors. Janice brings an unparalleled track record of financial, investor, and commercial real estate expertise, which will play a critical role in our future growth plans. Anshul is a biotech entrepreneur, experienced executive, philanthropist, and attorney, who will inform our work to develop innovative districts that meet the needs of leading life science companies while attracting top talent,” said CEO, Steve Rosetta.

About Janice Sears

Janice Searsis the Retired President of the San Francisco market of Bank of America. During her accomplished career at Bank of America, she also served as the West Coast Region Head for Real Estate Investment Banking, and the West Coast Region Head for Commercial Real Estate. Before joining Bank of America, she held prominent positions at Chemical Bank and Citigroup in New York City. Sears has served on numerous Boards, including current director roles for Sonder Holdings Inc. (NASDAQ: SOND) and Invitation Homes (NYSE: INVH). She holds a Bachelor of Science in Economics and Marketing from the University of Delaware.

“I am pleased and honored to be joining the Board of Directors at IQHQ and to work with a seasoned and talented management team, as well as a group of sophisticated life sciences investors,” said Janice Sears. “The pandemic has shown everyone the importance of this sector and IQHQ is extraordinarily well positioned to help the sector grow and thrive in key innovation markets.”

About Anshul Mangal

Anshul Mangal brings a wide range of entrepreneurial, management, and philanthropic experience to the Board. He currently serves as the founder and president of Project Farma (PF), a premier worldwide biologics and advanced therapy engineering consulting firm, and Precision ADVANCE, Precision Medicine Group’s cell, and gene collective. Mangal is also CSO for The Institute for Life Changing Medicines, a nonprofit organization that identifies, develops, and promotes access to life-changing medicines for diseases not considered commercially viable. Before PF, Mangal was a patent litigator at Jones Day and a pro bono attorney who helped refugees secure asylum in the United States. He earned a Bachelor of Science degree in Computer and Electrical Engineering from Purdue University and his Juris Doctor from the John Marshall Law School (now the University of Illinois Chicago School of Law).

“I am excited to join the IQHQ Board of Directors and use my expertise to further the development of IQHQ’s portfolio,” said Anshul Mangal. “I have been fortunate to work closely with life science leaders to improve the lives of patients, and am excited to further that work by helping these leaders have a place for their innovation to flourish via IQHQ.”

About IQHQ

IQHQ is giving progress a home, empowering the life science community to thrive and succeed by creating and developing districts that inspire innovation and drive progress and growth. IQHQ’s focus is to acquire, develop, and operate sustainable transformational life science districts in the innovation hubs of San Francisco, San Diego, and Boston in the United States, and the United Kingdom. IQHQ has offices in San Diego and Boston.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.